0	9	Tolerance	tolerance	NN
10	12	to	to	TO
13	31	lipopolysaccharide	lipopolysaccharide	NN
32	40	involves	involve	VBZ
41	53	mobilization	mobilization	NN
54	56	of	of	IN
57	64	nuclear	nuclear	JJ
65	71	factor	factor	NN
72	77	kappa	kappa	NN
78	79	B	b	NN
80	84	with	with	IN
85	97	predominance	predominance	NN
98	100	of	of	IN
101	104	p50	p50	NN
105	115	homodimers	homodimer	NNS
115	116	.	.	.

118	129	Stimulation	stimulation	NN
130	132	of	of	IN
133	136	the	the	DT
137	142	human	human	JJ
143	152	monocytic	monocytic	JJ
153	157	cell	cell	NN
158	162	line	line	NN
163	167	Mono	Mono	NNP
168	171	Mac	Mac	NNP
172	173	6	6	CD
174	178	with	with	IN
179	197	lipopolysaccharide	lipopolysaccharide	NN
198	199	(	(	(
199	202	LPS	LPS	NNP
202	203	)	)	)
204	209	leads	lead	VBZ
210	212	to	to	TO
213	218	rapid	rapid	JJ
219	222	and	and	CC
223	232	transient	transient	JJ
233	243	expression	expression	NN
244	246	of	of	IN
247	256	cytokines	cytokine	NNS
257	261	like	like	IN
262	267	tumor	tumor	NN
268	276	necrosis	necrosis	NN
277	283	factor	factor	NN
284	285	(	(	(
285	288	TNF	TNF	NNP
288	289	)	)	)
289	290	.	.	.

291	295	When	when	WRB
296	300	such	such	JJ
301	306	cells	cell	NNS
307	310	are	be	VBP
311	322	precultured	preculture	VBN
323	326	for	for	IN
327	328	2	2	CD
329	333	days	day	NNS
334	338	with	with	IN
339	340	a	a	DT
341	344	low	low	JJ
345	349	dose	dose	NN
350	352	of	of	IN
353	356	LPS	LPS	NNP
357	358	(	(	(
358	360	20	20	CD
361	366	ng/ml	ng/ml	NN
366	367	)	)	)
368	376	followed	follow	VBN
377	379	by	by	IN
380	391	stimulation	stimulation	NN
392	396	with	with	IN
397	398	a	a	DT
399	403	high	high	JJ
404	408	dose	dose	NN
409	411	of	of	IN
412	415	LPS	LPS	NNP
416	417	(	(	(
417	418	1	1	CD
419	431	microgram/ml	microgram/ml	NN
431	432	)	)	)
432	433	,	,	,
434	444	expression	expression	NN
445	447	of	of	IN
448	451	the	the	DT
452	455	TNF	TNF	NNP
456	460	gene	gene	NN
461	463	is	be	VBZ
464	471	minimal	minimal	JJ
471	472	,	,	,
473	477	i.e.	i.e.	FW
478	481	the	the	DT
482	487	cells	cell	NNS
488	491	are	be	VBP
492	500	tolerant	tolerant	JJ
500	501	.	.	.

502	504	In	in	IN
505	512	nuclear	nuclear	JJ
513	519	run-on	run-on	JJ
520	528	analysis	analysis	NN
528	529	,	,	,
530	534	such	such	JJ
535	543	tolerant	tolerant	JJ
544	549	cells	cell	NNS
550	554	show	show	VBP
555	559	only	only	RB
560	561	a	a	DT
562	565	low	low	JJ
566	572	degree	degree	NN
573	575	of	of	IN
576	589	transcription	transcription	NN
589	590	,	,	,
591	601	indicating	indicate	VBG
602	606	that	that	IN
607	616	tolerance	tolerance	NN
617	625	operates	operate	VBZ
626	628	at	at	IN
629	631	or	or	CC
632	640	upstream	upstream	RB
641	643	of	of	IN
644	647	the	the	DT
648	661	transcription	transcription	NN
662	667	level	level	NN
667	668	.	.	.

669	672	The	the	DT
673	677	CD14	cd14	NN
678	681	LPS	LPS	NNP
682	690	receptor	receptor	NN
691	693	is	be	VBZ
693	694	,	,	,
695	702	however	however	RB
702	703	,	,	,
704	716	up-regulated	up-regulate	VBN
717	718	(	(	(
718	721	not	not	RB
722	736	down-regulated	down-regulate	VBN
736	737	)	)	)
738	740	in	in	IN
741	749	tolerant	tolerant	JJ
750	755	cells	cell	NNS
755	756	,	,	,
757	760	and	and	CC
761	764	LPS	LPS	NNP
765	768	can	can	MD
768	769	,	,	,
770	772	in	in	IN
773	777	fact	fact	NN
777	778	,	,	,
779	784	still	still	RB
785	789	lead	lead	VB
790	792	to	to	TO
793	803	activation	activation	NN
804	806	of	of	IN
807	815	tolerant	tolerant	JJ
816	821	cells	cell	NNS
822	824	as	as	IN
825	834	evidenced	evidence	VBN
835	837	by	by	IN
838	850	mobilization	mobilization	NN
851	853	of	of	IN
854	857	the	the	DT
858	871	transcription	transcription	NN
872	878	factor	factor	NN
879	886	nuclear	nuclear	JJ
887	893	factor	factor	NN
894	899	kappa	kappa	NN
900	901	B	B	NNP
902	903	(	(	(
903	911	NF-kappa	NF-kappa	NNP
912	913	B	B	NNP
913	914	)	)	)
914	915	.	.	.

916	926	Resolution	Resolution	NNP
927	929	of	of	IN
930	933	the	the	DT
934	942	NF-kappa	NF-kappa	NNP
943	944	B	B	NNP
945	952	complex	complex	NN
953	955	in	in	IN
956	959	gel	gel	NN
960	965	shift	shift	NN
966	974	analysis	analysis	NN
975	980	shows	show	VBZ
981	985	that	that	IN
986	989	the	the	DT
990	997	binding	bind	VBG
998	1005	protein	protein	NN
1005	1006	,	,	,
1007	1016	mobilized	mobilize	VBN
1017	1019	in	in	IN
1020	1025	naive	naive	JJ
1026	1030	Mono	Mono	NNP
1031	1034	Mac	Mac	NNP
1035	1036	6	6	CD
1037	1042	cells	cell	NNS
1042	1043	,	,	,
1044	1052	consists	consist	VBZ
1053	1059	mainly	mainly	RB
1060	1062	of	of	IN
1063	1070	p50-p65	p50-p65	NN
1071	1083	heterodimers	heterodimer	NNS
1083	1084	,	,	,
1085	1090	while	while	IN
1091	1093	in	in	IN
1094	1102	tolerant	tolerant	JJ
1103	1108	cells	cell	NNS
1108	1109	,	,	,
1110	1113	the	the	DT
1114	1117	p50	p50	NN
1118	1127	homodimer	homodimer	NN
1128	1130	is	be	VBZ
1131	1142	predominant	predominant	JJ
1142	1143	.	.	.

1144	1148	This	this	DT
1149	1157	increase	increase	NN
1158	1160	in	in	IN
1161	1164	p50	p50	NN
1165	1175	homodimers	homodimer	NNS
1176	1185	coincides	coincide	VBZ
1186	1190	with	with	IN
1191	1193	an	an	DT
1194	1202	increase	increase	NN
1203	1205	in	in	IN
1206	1210	p105	p105	NN
1211	1215	mRNA	mrna	NN
1215	1216	,	,	,
1217	1227	suggestive	suggestive	JJ
1228	1230	of	of	IN
1231	1232	a	a	DT
1233	1248	transcriptional	transcriptional	JJ
1249	1262	up-regulation	up-regulation	NN
1263	1265	of	of	IN
1266	1269	p50	p50	NN
1269	1270	.	.	.

1271	1279	Reporter	reporter	NN
1280	1284	gene	gene	NN
1285	1293	analysis	analysis	NN
1294	1301	reveals	reveal	VBZ
1302	1306	that	that	IN
1307	1310	the	the	DT
1311	1319	NF-kappa	NF-kappa	NNP
1320	1321	B	B	NNP
1322	1329	complex	complex	NN
1330	1339	mobilized	mobilize	VBN
1340	1342	in	in	IN
1343	1351	tolerant	tolerant	JJ
1352	1357	cells	cell	NNS
1358	1360	is	be	VBZ
1361	1373	functionally	functionally	RB
1374	1382	inactive	inactive	JJ
1383	1385	in	in	IN
1386	1390	that	that	IN
1391	1399	NF-kappa	NF-kappa	NNP
1400	1411	B-dependent	b-dependent	JJ
1412	1422	luciferase	luciferase	NN
1423	1433	constructs	construct	NNS
1434	1444	containing	contain	VBG
1445	1448	the	the	DT
1449	1454	human	human	JJ
1455	1471	immunodeficiency	immunodeficiency	NN
1472	1477	virus	virus	NN
1478	1482	long	long	JJ
1483	1491	terminal	terminal	JJ
1492	1498	repeat	repeat	NN
1499	1501	or	or	CC
1502	1505	the	the	DT
1506	1509	TNF	TNF	NNP
1510	1519	5’-region	5'-region	NN
1520	1524	show	show	VBP
1525	1529	only	only	RB
1530	1537	minimal	minimal	JJ
1538	1553	transactivation	transactivation	NN
1554	1559	after	after	IN
1560	1563	LPS	LPS	NNP
1564	1575	stimulation	stimulation	NN
1575	1576	.	.	.

1577	1584	Similar	similar	JJ
1585	1587	to	to	TO
1588	1592	Mono	Mono	NNP
1593	1596	Mac	Mac	NNP
1597	1598	6	6	CD
1599	1604	cells	cell	NNS
1604	1605	,	,	,
1606	1613	primary	primary	JJ
1614	1619	blood	blood	NN
1620	1629	monocytes	monocyte	NNS
1629	1630	,	,	,
1631	1635	when	when	WRB
1636	1647	precultured	preculture	VBN
1648	1652	with	with	IN
1653	1654	a	a	DT
1655	1658	low	low	JJ
1659	1663	dose	dose	NN
1664	1666	of	of	IN
1667	1670	LPS	LPS	NNP
1670	1671	,	,	,
1672	1676	also	also	RB
1677	1683	become	become	VBP
1684	1692	tolerant	tolerant	JJ
1693	1696	and	and	CC
1697	1704	produce	produce	VBP
1705	1711	little	little	JJ
1712	1715	TNF	tnf	NN
1716	1721	after	after	IN
1722	1725	LPS	LPS	NNP
1726	1737	stimulation	stimulation	NN
1737	1738	.	.	.

1739	1742	The	the	DT
1743	1751	tolerant	tolerant	JJ
1752	1757	blood	blood	NN
1758	1767	monocytes	monocyte	NNS
1768	1772	also	also	RB
1773	1784	up-regulate	up-regulate	VBP
1785	1789	CD14	cd14	NN
1789	1790	,	,	,
1791	1794	and	and	CC
1795	1799	they	they	PRP
1800	1808	mobilize	mobilize	VBP
1809	1817	NF-kappa	NF-kappa	NNP
1818	1819	B	B	NNP
1820	1824	with	with	IN
1825	1826	a	a	DT
1827	1839	predominance	predominance	NN
1840	1842	of	of	IN
1843	1846	p50	p50	NN
1847	1857	homodimers	homodimer	NNS
1857	1858	.	.	.

1859	1864	Taken	take	VBN
1865	1873	together	together	RB
1873	1874	,	,	,
1875	1880	these	these	DT
1881	1888	results	result	NNS
1889	1900	demonstrate	demonstrate	VBP
1901	1905	that	that	IN
1906	1915	tolerance	tolerance	NN
1916	1918	to	to	TO
1919	1922	LPS	LPS	NNP
1923	1925	is	be	VBZ
1926	1936	determined	determine	VBN
1937	1939	by	by	IN
1940	1953	post-receptor	post-receptor	JJ
1954	1964	mechanisms	mechanism	NNS
1965	1969	that	that	WDT
1970	1977	involve	involve	VBP
1978	1980	an	an	DT
1981	1988	altered	altered	JJ
1989	2000	composition	composition	NN
2001	2003	of	of	IN
2004	2007	the	the	DT
2008	2016	NF-kappa	NF-kappa	NNP
2017	2018	B	B	NNP
2019	2026	complex	complex	NN
2026	2027	.	.	.